ECM
LAB icon

ExodusPoint Capital Management’s Standard BioTools LAB Stock Holding History

ExodusPoint Capital Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100,309
Closed -$194K – 1792
2024
Q3 		$194K Buy
+100,309
New +$196K ﹤0.01% 1457
2024
Q2 		– Sell
-304,495
Closed -$825K – 1764
2024
Q1 		$825K Buy
304,495
+232,470
+323% +$561K 0.01% 1003
2023
Q4 		$159K Buy
+72,025
New +$154K ﹤0.01% 1311
2023
Q1 		– Sell
-16,895
Closed -$20K – 1957
2022
Q4 		$20K Buy
+16,895
New +$20.8K ﹤0.01% 1567
2022
Q1 		– Sell
-13,357
Closed -$52K – 2448
2021
Q4 		$52K Sell
13,357
-22,895
-63% -$107K ﹤0.01% 2027
2021
Q3 		$239K Sell
36,252
-20,989
-37% -$138K ﹤0.01% 1715
2021
Q2 		$353K Buy
+57,241
New +$306K ﹤0.01% 1642
2021
Q1 		– Sell
-63,039
Closed -$378K – 2369
2020
Q4 		$378K Sell
63,039
-120,824
-66% -$794K ﹤0.01% 1415
2020
Q3 		$1.37M Buy
+183,863
New +$1.27M 0.03% 551

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

ExodusPoint Capital Management's LAB Position: Q4 2024 in Review

ExodusPoint Capital Management sold out of Standard BioTools (LAB) in Q4 2024, closing a stake of 100,309 shares — an estimated $194K sold.

ExodusPoint Capital Management first reported a position in LAB in Q3 2020 and held it in 9 quarters. The position peaked at $1.37M in Q3 2020. 142 funds tracked by Wall St. Rank hold LAB as of Q4 2024.

  • ExodusPoint Capital Management reported no remaining Standard BioTools position as of Q4 2024 after selling out during the quarter.
  • ExodusPoint Capital Management sold 100,309 Standard BioTools shares in Q4 2024, an estimated $194K.
  • ExodusPoint Capital Management first reported a position in Standard BioTools in Q3 2020 and held it in 9 quarters.
  • ExodusPoint Capital Management's Standard BioTools position peaked at $1.37M in Q3 2020.
  • 142 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2024.

Based on ExodusPoint Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.